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from the 200,000-cohort claim database of the National Health
Insurance (NHI). The prices, total amounts and the market
shares in different levels of health care setting were analyzed.
RESULTS: Among 5 SSRI antidepressants, ﬂuoxetine used
43.5% of the total SSRI expenditures. Compared with other
SSRIs, ﬂuoxetine also had the most number of different generic
items, the shortest time lags, higher prices of the generics, and the
fastest replacement rate by other generics. In 1997 the total
expenditure of ﬂuoxetine in medical centers and the district
hospitals was 82.8% and 17.2% in the local hospital and the
clinics. After the ﬁrst entry the original drug 15 years ago, the
market share of the original drug had shrunk to 1.46%. In
general the prices of original drugs fell 0–6.4% in the ﬁrst year
while the ﬁrst generic entered the market with the 80–87.7%
original price. CONCLUSION: This study presented the proﬁles
of generic competitions of SSRI antidepressants, which could
provide an approach for both policy maker and industry to
investigate the drug usage at national level. Except for ﬂuoxetine,
the generic market of SSRI antidepressants seem still promising.
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OBJECTIVE: To examine Texas Medicaid prescribers’ percep-
tions of the prior authorization (PA) process for non-preferred
psychotherapeutics among patients with severe mental illness.
METHODS: A 54-item survey instrument was used to assess the
perceived burden of prior authorization for psychotherapeutics
(BoPAP) held among mental health prescribers. The BoPAP
instrument was developed based on responses from three expert
focus group panels and was comprised of three sub-scales
(‘patient care process and outcomes’, ‘system/societal costs’, and
‘administrative issues’). The survey was pre-tested and then
mailed to 1650 Texas prescribers of psychiatric medications.
Exploratory factor analyses (EFA) techniques were used to reﬁne
the BoPAP scale(s). RESULTS: The study yielded an 18.3%
(n = 237) response rate with a majority of respondents being
family physicians (43%). Most (95.4%) reported treating
Medicaid patients. Respondents prescribed an average of 64
(Median = 40, SD = 102) Medicaid prescriptions per week with
17.8% requiring PA for non-preferred psychotherapeutics.
Overall, prescribers reported PA as a moderate burden (BoPAP
scale mean = 3.90, SD = 1.48; possible range 1 = ‘low burden’ to
5 = ‘high burden’) to their practice. Regarding the ‘administra-
tive issues’ subscale, respondents reported a moderate to strong
burden (Mean = 4.5, SD = 0.54); prescribers felt the PA process
led to uncompensated administrative time (Mean = 4.56,
SD = 0.63) and introduced an extra step in providing patient
care (Mean = 4.55, SD = 0.65). Prescribers reported a moderate
burden (Mean = 3.90, SD = 1.48) on the ‘patient care processes
and outcomes’ subscale, citing the PA process added another
level of bureaucracy (Mean = 4.51, SD = 0.64), led to patient
frustration (Mean = 4.21, SD = 0.77), and took focus away
from patient care (Mean = 4.08, SD = 0.87). The third sub-
scale, ‘system/social costs,’ was less burdensome (Mean = 3.29,
SD = 0.67) among respondents. CONCLUSION: Overall, Texas
mental health providers felt that the PA process negatively
impacted the quality and continuity of care they provide to their
mentally ill patients. Future studies should be conducted in other
states to determine the utility of the BoPAP instrument.
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OBJECTIVE: To describe the temporal prescribing patterns of
selective serotonin reuptake inhibitors (SSRI) and similar antide-
pressant medications among pediatric patients covered through a
state child health insurance and Medicaid program from 2000
through 2007. METHODS: Administrative claims data from
the health insurance programs of the Arkansas Department of
Human Services were examined from July 2000 through June
2007. Continuously eligible patients under age 18 were identiﬁed
in 14 6-month time periods. Pharmacy claims data identiﬁed all
covered recipients receiving a prescription for any antidepressant
obtained from an outpatient pharmacy. Considering published
data on use in children, antidepressant medications were char-
acterized as FDA approved, supported with evidence, lacking
adequate evidence, or relatively contraindicated. RESULTS:
Prevalence of SSRI and similar product use was 20 per 1000
children aged 6 to 12 years, and 48 per 1000 children aged 12 to
18 years in the initial 6 month period. Use peaked for 6 to 12
year old children at a rate of 24 per 1000 in the last half of 2002,
and for 12 to 18 year old children at a rate of 63 per thousand in
the ﬁrst half of 2004. In the ﬁrst half of 2007, the prevalence of
use was 16 per 1000 and 53 per 1000 for the younger and older
age groups respectively. Since 2002, the proportion of SSRI prod-
ucts with minimal or no supporting evidence of safety or effec-
tiveness in children increased from 20% to more than 45% of
patient treatments. CONCLUSION: Decreases in use of SSRI
and similar medications were seen among children covered by
Arkansas medical assistance plans after FDA advisories were
issued in 2003 and 2004. Additionally, young patients appear to
be increasingly treated with SSRI and similar medications having
minimal or no data supporting safety and effectiveness in chil-
dren or adolescents.
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OBJECTIVE: Anecdotal evidence suggests that prescribing of
ADHD therapies among children in the United States decreases
over the summer months when children and adolescents are out
of school. METHODS: We used retail pharmacy prescription
data to investigate monthly and annual ADHD prescribing
trends from January 2003 to October 2007 to determine if there
is any variation in prescribing, especially over the summer
months. The prescription data was obtained from Verispan’s
Vector One National (VONA), which captures nearly half of all
prescription activity in the United States. The Verispan prescrip-
tion data is age-speciﬁc; thus we were able to examine monthly
total prescriptions for two age groups: 0 to 17 years and 18 years
and older. RESULTS: There was a signiﬁcant dip in total pre-
scription volume in the summer months for the 0–17 age group.
The magnitude of the seasonality observed between May and
July ranged from a 22% to 29% decrease in total prescriptions,
depending on the year. In contrast, total prescriptions in the 18
and older age group have been rising steadily since January 2003,
and there is no observed seasonality. CONCLUSION: Our ﬁnd-
ings suggest that as many as 30% of children and adolescents use
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ADHD medications only during the school year and stop treat-
ment in the summer months. Assuming that a child meets the
DSM-IV-TR criteria for ADHD, taking him/her off treatment,
even outside the school setting, could impair his/her ability to
function in everyday life. At the same time, it provides the child
with a holiday from potentially serious side effects associated
with stimulant use. Further research is needed to compare these
and other beneﬁts/risks associated with discontinuing ADHD
therapy during the summer months.
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OBJECTIVE: To assess the impact of prior medication use and
comorbidities on treatment initiation with duloxetine vs. ven-
lafaxine XR for patients with major depression disorder (MDD)
using retrospective claims data. METHODS: Using the PharMet-
rics Database, we studied commercially insured individuals aged
18–64 who initiated treatment with duloxetine or venlafaxine
XR between July 2005 and July 2006, and had 1 prior diag-
nosis with MDD and continuous enrollment during 12 months
prior to initiation date. Initiation was deﬁned as the ﬁrst use of a
medication preceded by three months without a prescription of
the same medication. Chi-square and Logistic regression analysis
of patients’ demographics, past-year medication use and comor-
bidities assessed predictors of initiations with duloxetine vs.
venlafaxine XR. RESULTS: A total of 12,662 patients (73.8%
female) initiated treatment with duloxetine, and 14,801 (72.1%
female) with venlafaxine XR. Compared to venlafaxine XR
patients, signiﬁcantly more duloxetine patients received 3
unique antidepressants (39.5% vs. 25.2%), 3 unique pain
medications (25.8% vs. 15.1%), SSRIs (55.5% vs. 41.2%),
TCAs (12.5% vs. 7.5%), analgesics (63.6% vs. 51.6%), anticon-
vulsants (31.3% vs. 19.2%), or hypnotics (31.5% vs. 22.0%),
and had 8 unique co-morbid medical conditions (38.8% vs.
29.5%) and diagnoses with pain (76.4% vs. 67.1%) (all p-values
<0.001). Regression results revealed that the signiﬁcant factors
for duloxetine initiation vs. venlafaxine XR were prior use of 3
unique antidepressants (OR = 1.34), 3 unique pain medi-
cations (OR = 1.24), SSRIs (OR = 1.51), TCAs (OR = 1.19),
analgesics (OR = 1.12), anticonvulsants (OR = 1.45), hypno-
tics (OR = 1.25), and prior medical comorbidities of pain
(OR = 1.11) (all p-values <0.001). CONCLUSION: The results
suggest that duloxetine patients with MDD are more likely to
have more medical conditions and complex prior medication
treatments than venlafaxine XR patients.
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OBJECTIVE: This study examined the health service utilization
and treatment costs among depression patients who received
antidepressant medication, psychotherapy or both. METHODS:
This study used medical and pharmacy claims data from 220,620
employees from three employer groups from September 2002 to
December 2003. Depression patients (n = 4653) were identiﬁed
using ICD-9 diagnosis codes from medical claims data. Differ-
ences in treatment costs and comorbid conditions were examined
between depression patients who received psychotherapy and
those who did not. RESULTS: Among eligible members, 4,653
(2.1%) had a primary diagnosis of depression. Nearly 70% were
female with an average age of 39.7 years. Approximately half of
the depression patients (46.9%) received antidepressant medica-
tion alone while 34.2% of patients received both psychotherapy
and medication. Only 19.3% of depression patients received
psychotherapy without medications. The average total treatment
cost for depression patients who received both psychotherapy
and medications was $10,565, while the average treatment cost
for patients who only used medication was $10,014. These treat-
ment costs were not signiﬁcantly different. The average treatment
cost for psychotherapy alone was $3,945. The most frequent
comorbid conditions among depression patients were muscu-
loskeletal and chronic pain (29.9%), anxiety (26.6%), injuries
(18.7%), hypertension (14.4%), asthma (6.5%), diabetes
(6.1%), arthritis (5.4%), urinary tract infection (4.4%) and drug
dependence and alcohol abuse (4.1%). Depression patients who
received both medication and psychotherapy had signiﬁcantly
more comorbid anxiety (33.1%) and drug and alcohol abuse
(5.8%) than those who received medications or psychotherapy
alone (p < 0.001). CONCLUSION: Depression patients who
used psychotherapy including antidepressant medications did
not have signiﬁcantly different health care costs than depression
patients who did not receive psychotherapy treatments. Depres-
sion patients with comorbid psychological conditions such as
anxiety or drug abuse were more likely to receive psychotherapy
treatment (p < 0.001).
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OBJECTIVE: Those with BPD often present when depressed
leading to potential misdiagnosed and treatment as depression,
particularly in primary care. Inappropriate treatment increases
risk for suicide and rapid cycling. STABLE was initiated to
develop and ﬁeld test evidence-based clinical performance mea-
sures (PM) for endorsment by the National Quality Forum, and
eventual implementation for quality improvement. METHODS:
An expert panel used a validated method to develop 15 perfor-
mance measures for BPD and depression. Field testing was
conducted on 802 medical records among 80 practices (48 psy-
chiatry, 32 primary care) in 28 states. Feasibility was evaluated
using standard parameters with inter-rater reliability evaluated
in a subset of records (proportion agreement and kappa).
RESULTS: Fifteen measures were developed and validated in
four domains: initial assessment, appropriate pharmacotherapy,
adjunctive treatment, monitoring treatment response and
antipsychotic-related metabolic changes. A total of 802 cases
(419 BPD; 383 depression) were audited. In those with depres-
sive symptoms, primary care and specialists assessed patients
for mania or family history of mental health disorders in only
47.6% and 40.8%, respectively. Suicide risk assessment was
only conducted in 71.5% of patients, and substance abuse
assessment in only 60.5%. For BPD speciﬁc measures, results
indicated adequate assessment of functional status at baseline
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